Liu, Liang <br/><br/>
RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.  [electronic resource] 

 -  Leukemia research  Aug 2011 
 - 1020-6 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2011.01.014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Case-Control Studies<br/>Child<br/>Child, Preschool<br/>Chromosome Inversion<br/>Chromosomes, Human, Pair 16--genetics<br/>DNA, Neoplasm--genetics<br/>DNA-Binding Proteins--genetics<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Humans<br/>Leukemia, Myeloid, Acute--genetics<br/>Male<br/>Middle Aged<br/>Oncogene Proteins, Fusion--genetics<br/>Polymerase Chain Reaction<br/>Polymorphism, Genetic--genetics<br/>Polymorphism, Restriction Fragment Length<br/>Rad51 Recombinase--genetics<br/>Retrospective Studies<br/>Survival Rate<br/>Translocation, Genetic<br/>Treatment Outcome<br/>Young Adult